Irisin, two years later
In January 2012, Boström and colleagues identified a new muscle tissue secreted peptide, which they named irisin, to highlight its role as a messenger that comes from skeletal muscle to other parts of the body. Irisin is a cleaved and secreted fragment of FNDC5 (also known as FRCP2 and PeP), a membe...
| Authors: | ; ; ; ; |
|---|---|
| Format: | Article |
| Publication date: | 2013 |
| Country: | España |
| Institution: | Universidad Complutense de Madrid (UCM) |
| Repository: | Docta Complutense |
| Language: | English |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/94891 |
| Online Access: | https://hdl.handle.net/20.500.14352/94891 |
| Access Level: | Open access |
| Keyword: | 577.17 Farmacología (Medicina) Medicamentos 2411.04 Fisiología Endocrina 3206.10 Enfermedades de la Nutrición |
| _version_ | 1878734222333575168 |
|---|---|
| author | Garrido Novelle, Marta |
| author2 | Contreras Jiménez, Cristina Romero Picó, Amparo López, Miguel Diéguez, Carlos |
| author2_role | author author author author |
| author_browse | Contreras Jiménez, Cristina Diéguez, Carlos Garrido Novelle, Marta López, Miguel Romero Picó, Amparo |
| author_facet | Garrido Novelle, Marta Contreras Jiménez, Cristina Romero Picó, Amparo López, Miguel Diéguez, Carlos |
| author_role | author |
| collection | Docta Complutense |
| description | In January 2012, Boström and colleagues identified a new muscle tissue secreted peptide, which they named irisin, to highlight its role as a messenger that comes from skeletal muscle to other parts of the body. Irisin is a cleaved and secreted fragment of FNDC5 (also known as FRCP2 and PeP), a member of fibronectin type III repeat containing gene family. Major interest in this protein arose because of its great therapeutic potential in diabetes and perhaps also therapy for obesity. Here we review the most important aspects of irisin’s action and discuss its involvement in energy and metabolic homeostasis and whether the beneficial effects of exercise in these disease states could be mediated by this protein. In addition the effects of irisin at the central nervous system (CNS) are highlighted. It is concluded that although current and upcoming research on irisin is very promising it is still necessary to deepen in several aspects in order to clarify its full potential as a meaningful drug target in human disease states. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_65b5e94d2baf2b7fcd5da2f73d84480f |
| institution | Universidad Complutense de Madrid (UCM) |
| instname_str | Universidad Complutense de Madrid (UCM) |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:docta.ucm.es:20.500.14352/94891 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | Wiley |
| publisherStr | Wiley |
| reponame_str | Docta Complutense |
| spelling | Irisin, two years later Garrido Novelle, Marta Contreras Jiménez, Cristina Romero Picó, Amparo López, Miguel Diéguez, Carlos 577.17 Farmacología (Medicina) Medicamentos 2411.04 Fisiología Endocrina 3206.10 Enfermedades de la Nutrición In January 2012, Boström and colleagues identified a new muscle tissue secreted peptide, which they named irisin, to highlight its role as a messenger that comes from skeletal muscle to other parts of the body. Irisin is a cleaved and secreted fragment of FNDC5 (also known as FRCP2 and PeP), a member of fibronectin type III repeat containing gene family. Major interest in this protein arose because of its great therapeutic potential in diabetes and perhaps also therapy for obesity. Here we review the most important aspects of irisin’s action and discuss its involvement in energy and metabolic homeostasis and whether the beneficial effects of exercise in these disease states could be mediated by this protein. In addition the effects of irisin at the central nervous system (CNS) are highlighted. It is concluded that although current and upcoming research on irisin is very promising it is still necessary to deepen in several aspects in order to clarify its full potential as a meaningful drug target in human disease states. Wiley https://hdl.handle.net/20.500.14352/94891 |
| spellingShingle | Irisin, two years later Garrido Novelle, Marta 577.17 Farmacología (Medicina) Medicamentos 2411.04 Fisiología Endocrina 3206.10 Enfermedades de la Nutrición |
| title | Irisin, two years later |
| title_full | Irisin, two years later |
| title_fullStr | Irisin, two years later |
| title_full_unstemmed | Irisin, two years later |
| title_short | Irisin, two years later |
| title_sort | Irisin, two years later |
| topic | 577.17 Farmacología (Medicina) Medicamentos 2411.04 Fisiología Endocrina 3206.10 Enfermedades de la Nutrición |
| topic_facet | 577.17 Farmacología (Medicina) Medicamentos 2411.04 Fisiología Endocrina 3206.10 Enfermedades de la Nutrición |
| url | https://hdl.handle.net/20.500.14352/94891 |